The ERBB family, crucial in cancer cell biology, is a target for various anticancer agents, including monoclonal antibodies, small-molecule tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), peptide-based inhibitors, immunotoxins, and heat-shock protein inhibitors. This evidence concerns the gene EGFR and cancer.